MedPath

SIHUAN PHARM

SIHUAN PHARM logo
🇨🇳China
Ownership
Public
Established
2010-10-06
Employees
2.6K
Market Cap
-
Website
http://www.sihuanpharm.com
Introduction

Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.

thebambooworks.com
·

Suhuan Pharma stock skyrockets on latest share buyback program

Sihuan Pharmaceutical Holdings Group Ltd. announced a new program to buy back up to HK$500 million of its shares over 12 months, supported by a strong portfolio of innovative drugs and diabetes biosimilars. The company, originally focused on cardiovascular and oncology generic drugs, expanded into medical aesthetics in 2021. Despite a 10% revenue drop in H1 2024, medical aesthetics revenue surged 66.4%. Shares surged 23.6% to a 52-week high.
© Copyright 2025. All Rights Reserved by MedPath